Regrettably, although a phase I/IIa clinical trial showed that the administration of an antisense oligonucleotide to lower SOD1 expression in ALS patients was safe [195], a subsequent study very recently failed to demonstrate that the intervention slowed disease progression [196]. This evidence concerns the gene SOD1 and amyotrophic lateral sclerosis.